Alaunos Therapeutics, Inc. Operating Costs and Expenses
Alaunos Therapeutics, Inc. (TCRT) reported Operating Costs and Expenses of $22.77 million for the 3-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingCostsAndExpenses · last filed 2021-03-01
- Alaunos Therapeutics, Inc. operating costs and expenses for the quarter ending 2020-12-31 was $22.77M, a 42.02% increase year-over-year.
- Alaunos Therapeutics, Inc. operating costs and expenses for the quarter ending 2020-09-30 was $20.32M, a 51.11% increase year-over-year.
- Alaunos Therapeutics, Inc. operating costs and expenses for the quarter ending 2020-06-30 was $18.61M, a 26.12% increase year-over-year.
- Alaunos Therapeutics, Inc. operating costs and expenses for the quarter ending 2020-03-31 was $18.66M, a 36.99% increase year-over-year.
- Alaunos Therapeutics, Inc. operating costs and expenses for fiscal 2018 was $54.05M, a 9.74% decline from fiscal 2017.
- Alaunos Therapeutics, Inc. operating costs and expenses for fiscal 2017 was $59.88M, a 65.22% decline from fiscal 2016.
- Alaunos Therapeutics, Inc. operating costs and expenses for fiscal 2016 was $172.17M, a 38.36% increase from fiscal 2015.
- Alaunos Therapeutics, Inc. operating costs and expenses for fiscal 2015 was $124.43M, a 177.30% increase from fiscal 2014.
| Period end | Operating Costs and Expenses 3 month | Operating Costs and Expenses 6 month | Operating Costs and Expenses 9 month | Operating Costs and Expenses 12 month | Operating Costs and Expenses 85 month | Operating Costs and Expenses 94 month | Operating Costs and Expenses 97 month | Operating Costs and Expenses 100 month | Operating Costs and Expenses 103 month | Operating Costs and Expenses 106 month | Operating Costs and Expenses 109 month | Operating Costs and Expenses 112 month | Operating Costs and Expenses 115 month | Operating Costs and Expenses 118 month | Operating Costs and Expenses 121 month | Operating Costs and Expenses 124 month | Operating Costs and Expenses 127 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | $22.77M 10-K · filed 2021-03-01 | $43.09M derived: sum of 2 quarters · filed 2021-03-01 | $61.70M derived: sum of 3 quarters · filed 2021-03-01 | $80.36M derived: sum of 4 quarters · filed 2021-03-01 | |||||||||||||
| 2020-09-30 | $20.32M 10-K · filed 2021-03-01 | $38.93M derived: sum of 2 quarters · filed 2021-03-01 | $57.59M derived: sum of 3 quarters · filed 2021-03-01 | $73.62M derived: sum of 4 quarters · filed 2021-03-01 | |||||||||||||
| 2020-06-30 | $18.61M 10-K · filed 2021-03-01 | $37.27M derived: sum of 2 quarters · filed 2021-03-01 | $53.30M derived: sum of 3 quarters · filed 2021-03-01 | $66.75M derived: sum of 4 quarters · filed 2021-03-01 | |||||||||||||
| 2020-03-31 | $18.66M 10-K · filed 2021-03-01 | $34.70M derived: sum of 2 quarters · filed 2021-03-01 | $48.14M derived: sum of 3 quarters · filed 2021-03-01 | $62.90M derived: sum of 4 quarters · filed 2021-03-01 | |||||||||||||
| 2019-12-31 | $16.04M 10-K · filed 2021-03-01 | $29.48M derived: sum of 2 quarters · filed 2021-03-01 | $44.24M derived: sum of 3 quarters · filed 2021-03-01 | $57.86M derived: sum of 4 quarters · filed 2021-03-01 | |||||||||||||
| 2019-09-30 | $13.45M 10-K · filed 2021-03-01 | $28.20M derived: sum of 2 quarters · filed 2021-03-01 | $41.82M derived: sum of 3 quarters · filed 2021-03-01 | $54.58M derived: sum of 4 quarters · filed 2021-03-01 | |||||||||||||
| 2019-06-30 | $14.75M 10-K · filed 2021-03-01 | $28.37M derived: sum of 2 quarters · filed 2021-03-01 | $41.14M derived: sum of 3 quarters · filed 2021-03-01 | $53.71M derived: sum of 4 quarters · filed 2021-03-01 | |||||||||||||
| 2019-03-31 | $13.62M 10-K · filed 2021-03-01 | $26.38M derived: sum of 2 quarters · filed 2021-03-01 | $38.95M derived: sum of 3 quarters · filed 2021-03-01 | $51.33M derived: sum of 4 quarters · filed 2021-03-01 | |||||||||||||
| 2018-12-31 | $12.76M 10-K · filed 2020-03-02 | $25.33M derived: sum of 2 quarters · filed 2020-03-02 | $37.71M derived: sum of 3 quarters · filed 2020-03-02 | $54.05M 10-K · filed 2019-03-05 | |||||||||||||
| 2018-09-30 | $12.57M 10-K · filed 2020-03-02 | $24.95M derived: sum of 2 quarters · filed 2020-03-02 | $41.29M 10-Q · filed 2018-11-09 | $56.32M derived: sum of 4 quarters · filed 2020-03-02 | |||||||||||||
| 2018-06-30 | $12.38M 10-K · filed 2020-03-02 | $28.72M 10-Q · filed 2018-08-08 | $43.75M derived: sum of 3 quarters · filed 2020-03-02 | $58.43M derived: sum of 4 quarters · filed 2020-03-02 | |||||||||||||
| 2018-03-31 | $16.34M 10-K · filed 2020-03-02 | $31.38M derived: sum of 2 quarters · filed 2020-03-02 | $46.05M derived: sum of 3 quarters · filed 2020-03-02 | $60.66M derived: sum of 4 quarters · filed 2020-03-02 | |||||||||||||
| 2017-12-31 | $15.03M 10-K · filed 2019-03-05 | $29.71M derived: sum of 2 quarters · filed 2019-03-05 | $44.32M derived: sum of 3 quarters · filed 2019-03-05 | $59.88M 10-K · filed 2019-03-05 | |||||||||||||
| 2017-09-30 | $14.68M 10-K · filed 2019-03-05 | $29.29M derived: sum of 2 quarters · filed 2019-03-05 | $44.85M 10-Q · filed 2018-11-09 | $57.56M derived: sum of 4 quarters · filed 2019-03-05 | |||||||||||||
| 2017-06-30 | $14.61M 10-K · filed 2019-03-05 | $30.17M 10-Q · filed 2018-08-08 | $42.88M derived: sum of 3 quarters · filed 2019-03-05 | $55.39M derived: sum of 4 quarters · filed 2019-03-05 | |||||||||||||
| 2017-03-31 | $15.56M 10-K · filed 2019-03-05 | $28.27M derived: sum of 2 quarters · filed 2019-03-05 | $40.78M derived: sum of 3 quarters · filed 2019-03-05 | $173.72M derived: sum of 4 quarters · filed 2019-03-05 | |||||||||||||
| 2016-12-31 | $12.71M 10-K · filed 2018-03-01 | $25.22M derived: sum of 2 quarters · filed 2018-03-01 | $158.16M derived: sum of 3 quarters · filed 2018-03-01 | $172.17M 10-K · filed 2019-03-05 | |||||||||||||
| 2016-09-30 | $12.51M 10-Q · filed 2017-11-06 | $145.45M derived: sum of 2 quarters · filed 2018-03-01 | $159.46M 10-Q · filed 2017-11-06 | $170.86M derived: sum of 4 quarters · filed 2018-03-01 | |||||||||||||
| 2016-06-30 | $132.94M 10-K · filed 2018-03-01 | $146.95M 10-Q · filed 2017-07-31 | $158.35M derived: sum of 3 quarters · filed 2018-03-01 | $178.38M derived: sum of 4 quarters · filed 2018-03-01 | |||||||||||||
| 2016-03-31 | $14.01M 10-K · filed 2018-03-01 | $25.41M derived: sum of 2 quarters · filed 2018-03-01 | $45.45M derived: sum of 3 quarters · filed 2018-03-01 | $59.94M derived: sum of 4 quarters · filed 2018-03-01 | |||||||||||||
| 2015-12-31 | $11.40M 10-K · filed 2017-02-16 | $31.44M derived: sum of 2 quarters · filed 2017-02-16 | $45.93M derived: sum of 3 quarters · filed 2017-02-16 | $124.43M 10-K · filed 2018-03-01 | |||||||||||||
| 2015-09-30 | $20.04M 10-K · filed 2017-02-16 | $34.53M derived: sum of 2 quarters · filed 2017-02-16 | $113.03M 10-Q · filed 2016-11-09 | $123.97M derived: sum of 4 quarters · filed 2017-02-16 | |||||||||||||
| 2015-06-30 | $14.50M 10-K · filed 2017-02-16 | $93.00M 10-Q · filed 2016-08-09 | $103.93M derived: sum of 3 quarters · filed 2017-02-16 | $116.51M derived: sum of 4 quarters · filed 2017-02-16 | |||||||||||||
| 2015-03-31 | $78.50M 10-K · filed 2017-02-16 | $89.44M derived: sum of 2 quarters · filed 2017-02-16 | $102.01M derived: sum of 3 quarters · filed 2017-02-16 | $113.39M derived: sum of 4 quarters · filed 2017-02-16 | |||||||||||||
| 2014-12-31 | $10.94M 10-K · filed 2016-02-24 | $23.51M derived: sum of 2 quarters · filed 2016-02-24 | $34.89M derived: sum of 3 quarters · filed 2016-02-24 | $44.87M 10-K · filed 2017-02-16 | |||||||||||||
| 2014-09-30 | $12.57M 10-K · filed 2016-02-24 | $23.95M derived: sum of 2 quarters · filed 2016-02-24 | $33.94M 10-Q · filed 2015-11-02 | $40.85M derived: sum of 4 quarters · filed 2016-02-24 | |||||||||||||
| 2014-06-30 | $11.38M 10-K · filed 2016-02-24 | $21.36M 10-Q · filed 2015-08-10 | $28.28M derived: sum of 3 quarters · filed 2016-02-24 | $37.59M derived: sum of 4 quarters · filed 2016-02-24 | |||||||||||||
| 2014-03-31 | $9.98M 10-K · filed 2016-02-24 | $16.90M derived: sum of 2 quarters · filed 2016-02-24 | $26.22M derived: sum of 3 quarters · filed 2016-02-24 | $44.71M derived: sum of 4 quarters · filed 2016-02-24 | $369.16M 10-Q · filed 2014-05-08 | ||||||||||||
| 2013-12-31 | $6.92M 10-K · filed 2015-02-26 | $16.23M derived: sum of 2 quarters · filed 2015-02-26 | $34.73M derived: sum of 3 quarters · filed 2015-02-26 | $58.51M 10-K · filed 2016-02-24 | $359.18M 10-K · filed 2014-03-03 | ||||||||||||
| 2013-09-30 | $9.31M 10-K · filed 2015-02-26 | $27.81M derived: sum of 2 quarters · filed 2015-02-26 | $51.59M 10-Q · filed 2014-10-30 | $90.64M derived: sum of 4 quarters · filed 2015-02-26 | $352.25M 10-Q · filed 2013-10-22 | ||||||||||||
| 2013-06-30 | $18.50M 10-Q · filed 2014-08-07 | $42.28M 10-Q · filed 2014-08-07 | $81.32M derived: sum of 3 quarters · filed 2015-02-26 | $103.25M derived: sum of 4 quarters · filed 2015-02-26 | $342.94M 10-Q · filed 2013-08-08 | ||||||||||||
| 2013-03-31 | $23.78M 10-K · filed 2015-02-26 | $62.83M derived: sum of 2 quarters · filed 2015-02-26 | $84.75M derived: sum of 3 quarters · filed 2015-02-26 | $107.92M derived: sum of 4 quarters · filed 2015-02-26 | $324.45M 10-Q · filed 2013-05-07 | ||||||||||||
| 2012-12-31 | $39.04M 10-K · filed 2014-03-03 | $60.97M derived: sum of 2 quarters · filed 2014-03-03 | $84.14M derived: sum of 3 quarters · filed 2014-03-03 | $102.97M 10-K · filed 2015-02-26 | $300.66M 10-K · filed 2013-03-18 | ||||||||||||
| 2012-09-30 | $21.93M 10-K · filed 2014-03-03 | $45.09M derived: sum of 2 quarters · filed 2014-03-03 | $63.93M 10-Q · filed 2013-10-22 | $80.54M derived: sum of 4 quarters · filed 2014-03-03 | $261.62M 10-Q · filed 2012-11-08 | ||||||||||||
| 2012-06-30 | $23.17M 10-K · filed 2014-03-03 | $42.00M 10-Q · filed 2013-08-08 | $58.62M derived: sum of 3 quarters · filed 2014-03-03 | $73.03M derived: sum of 4 quarters · filed 2014-03-03 | $239.69M 10-Q/A · filed 2012-08-28 | ||||||||||||
| 2012-03-31 | $18.83M 10-K · filed 2014-03-03 | $35.45M derived: sum of 2 quarters · filed 2014-03-03 | $49.86M derived: sum of 3 quarters · filed 2014-03-03 | $62.91M derived: sum of 4 quarters · filed 2014-03-03 | $216.53M 10-Q · filed 2012-05-03 | ||||||||||||
| 2011-12-31 | $16.62M 10-K · filed 2013-03-18 | $31.03M derived: sum of 2 quarters · filed 2013-03-18 | $44.07M derived: sum of 3 quarters · filed 2013-03-18 | $72.07M 10-K · filed 2014-03-03 | $197.69M 10-K · filed 2012-02-29 | ||||||||||||
| 2011-09-30 | $14.41M 10-K · filed 2013-03-18 | $27.46M derived: sum of 2 quarters · filed 2013-03-18 | $55.45M 10-Q · filed 2012-11-08 | $61.81M derived: sum of 4 quarters · filed 2013-03-18 | $181.08M 10-Q · filed 2011-11-03 | ||||||||||||
| 2011-06-30 | $13.05M 10-K · filed 2013-03-18 | $41.04M 10-Q/A · filed 2012-08-28 | $47.40M derived: sum of 3 quarters · filed 2013-03-18 | $55.90M derived: sum of 4 quarters · filed 2013-03-18 | $166.67M 10-Q/A · filed 2011-08-09 | ||||||||||||
| 2011-03-31 | $27.99M 10-K · filed 2013-03-18 | $34.35M derived: sum of 2 quarters · filed 2013-03-18 | $42.85M derived: sum of 3 quarters · filed 2013-03-18 | $47.97M derived: sum of 4 quarters · filed 2013-03-18 | |||||||||||||
| 2010-12-31 | $6.36M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $14.86M derived: sum of 2 quarters · filed 2013-03-18 | $19.98M derived: sum of 3 quarters · filed 2013-03-18 | $24.55M 10-K · filed 2013-03-18 | |||||||||||||
| 2010-09-30 | $8.50M 10-Q · filed 2011-11-03 | $13.62M derived: sum of 2 quarters · filed 2011-11-03 | $18.18M 10-Q · filed 2011-11-03 | $119.27M 10-Q · filed 2011-08-01 | |||||||||||||
| 2010-06-30 | $5.12M 10-Q/A · filed 2011-08-09 | $9.69M 10-Q/A · filed 2011-08-09 | |||||||||||||||
| 2009-12-31 | $4.03M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $6.60M derived: sum of 2 quarters · filed 2012-02-29 | $12.12M 10-K · filed 2012-02-29 | ||||||||||||||
| 2009-09-30 | $2.57M 10-Q · filed 2011-08-01 | $8.09M 10-Q · filed 2011-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |